SciLeads
SciLeads

BioPharma Updates 7th July, 2025

BioPharma Updates, July 7th, 2025.

SciLeads’ BioPharma is updated daily, giving our clients the most current insights on biopharma organizations including Funding, Initial Public Offerings, Mergers & Acquisitions, Partnerships, and more. This week’s updates are below, with links to the organizations in the platform. If you don’t have BioPharma yet, start your free trial today.

Download this update:

View BioPharma updates as a PDF.
View BioPharma updates in an Excel (.XLS) format.

Funding

  • Kardium (Vancouver, Canada) raised $250M in funding to support the commercial launch of its Globe Pulsed Field System for atrial fibrillation, expand manufacturing, and build out its clinical and commercial teams. 
  • AvenCell Japan (Tokyo, Japan) received a $40M AMED grant to advance the global development of AVC203, its dual-antigen allogeneic CAR-T therapy for B-cell lymphomas. 
  • Field Medical (CA, USA) raised $35M in Series B funding to initiate a pivotal trial and advance the development of its FieldForce Ablation System, a next-generation pulsed field ablation platform for treating ventricular tachycardia. 
  • Syntis Bio (MA, USA) raised $33M in Series A funding and secured up to $5M in NIH grants to advance its SYNT platform and support clinical development of oral therapies for obesity and homocystinuria. 
  • Adagene (Suzhou, China) raised up to $25M in funding to support clinical development of its anti-CTLA-4 SAFEbody, muzastotug, including a Phase 2 trial in microsatellite stable colorectal cancer and combination studies in advanced solid tumors. 
  • Laverock Therapeutics (London, United Kingdom) raised $25M in Seed funding to advance its programmable gene control therapies and support partnership and out-licensing activities across oncology and genetic medicine. 
  • Gallant (CA, USA) raised $18M in Series B funding to advance the development and commercial rollout of its off-the-shelf stem cell therapy for Feline Chronic Gingivostomatitis and expand its pipeline targeting osteoarthritis, atopic dermatitis, and chronic kidney disease in pets. 
  • FELIQS (Fukuoka, Japan) raised $9M in Series A funding to advance clinical development of FLQ-101, its lead oral and IV therapy for preventing retinopathy of prematurity in neonates, ahead of a Phase 1b/2 trial launch in the U.S. 
  • Primo Biotechnology (Taipei, Taiwan) raised $6.8M in Series A funding to advance its radioligand theranostics pipeline and expand the development of precision radiodiagnostics and therapeutics for cancer.
  • Escala Medical (Misgav, Israel) raised $4.5M in funding to expand U.S. commercial operations for its FDA-approved pelvic organ prolapse device and prepare for market entry in Europe and Southeast Asia. 
  • Adiposs (Geneva, Switzerland) raised $4.5M in Series A funding to advance clinical development of ImageBAT®, a novel imaging agent for non-invasive CT detection of brown fat in cancer patients to help identify early non-responders to therapy.
  • Quiver Bioscience (MA, USA) received a $2.15M NIH grant to advance the development of its platform for predicting neurotoxicity in CNS-targeted antisense oligonucleotide therapies. 
  • Stalicla (Geneva, Switzerland) raised $2M in funding to support operations and advance its precision neurodevelopmental disorder programs as it prepares for a Series C round and strategic partnering efforts. 
  • Lamark Biotech (Ahmedabad, India) raised $780K in pre-Series A funding to advance the development of its thermostable insulin formulation and expand its pipeline of temperature-resilient biologics. 
  • Loto Biotech (L’Aquila, Italy) raised $650K in funding to advance the development of its AI-driven platform for designing siRNA-based pro-drugs targeting rare autosomal dominant genetic disorders. 

Emerging

  • Portal Biotech (London, United Kingdom) emerged from stealth with $35M in Series A funding to accelerate the development and commercialization of its AI-powered platform for full-length single-molecule protein sequencing, aiming to transform drug discovery, diagnostics, and biosecurity. 
  • Circulate Health (CA, USA) emerged from stealth with $12M in seed funding to expand access to therapeutic plasma exchange treatments aimed at extending health span and reducing biological age. 
  • Juniper Genomics (Toronto, Canada) launched with $4.6M in seed funding to introduce a new standard for IVF genetic testing through the world’s first whole-genome and transcriptome embryo screening platform. 
  • Dionysus Health (CA, USA) emerged from stealth to tackle postpartum depression with their molecular diagnostics platform, myLuma™, the first clinically validated prenatal blood test designed to predict a woman’s risk of postpartum depression as early as 28 weeks into pregnancy. 

Post IPO Equity

  • Dyne Therapeutics (MA, USA) raised $200M through a public offering of common stock to support the advancement of its clinical programs for neuromuscular diseases including DM1 and DMD.
  • ArriVent BioPharma (PA, USA) raised $75M through an underwritten public offering of common stock and pre-funded warrants to support firmonertinib development, pipeline programs, and general corporate purposes.
  • Atai Life Sciences (Berlin, Germany) raised $50M through a private placement of ordinary shares and pre-funded warrants to advance its mental health treatment pipeline and support general corporate operations.
  • INOVIO Pharmaceuticals (PA, USA)raised $25M through a public offering of common stock and accompanying warrants to support the company’s development and commercialization of DNA medicines for HPV-related diseases, cancer, and infectious diseases.
  • Oragenics (FL, USA) raised $16.5M to fund ONP-2 concussion trials, repay a bridge note, and support general corporate purposes.
  • Cellectar Biosciences (NJ, USA) raised $6.9M through an underwritten public offering of common stock, pre-funded warrants, and common warrants to fund general corporate purposes and initiate a Phase 1b trial of CLR 125 in triple-negative breast cancer.
  • Lixte Biotechnology Holdings, Inc. (CA, USA) raised $5M through a private placement to support general corporate purposes and working capital.
  • Reborna Biosciences, Inc. (Fujisawa, Japan) raised ~$4.8M through a third-party equity allotment to advance preclinical trials of its RNA-targeting small molecule pipeline and strengthen its proprietary drug discovery platform.
  • NLS Pharmaceutics AG (Zürich, Switzerland) raised $1M through the private placement of preferred shares and warrants in two tranches to support its pending merger with Kadimastem and fund working capital and general corporate activities.
  • Nektar Therapeutics (CA, USA) announced a proposed public offering of common stock and pre-funded warrants to support the advancement of its immunotherapy pipeline, including rezpegaldesleukin and other candidates.

Post IPO debt

  • Dyne Therapeutics (MA, USA) raised $275M through a non-dilutive senior secured term loan facility with Hercules Capital to support clinical and regulatory milestones for DYNE-101 and DYNE-251, with $100M funded upfront and additional tranches tied to future progress.
  • Indaptus Therapeutics, Inc. (NY, USA) raised $5.7M through a private placement of convertible promissory notes and warrants to support a Phase 1b/2 trial, R&D activities, and general corporate operations.
  • Celadon Pharmaceuticals (London, United Kingdom) raised ~$1.9M through a secured credit facility from a European high-net-worth lender to support working capital, capital expenditures, and general corporate purposes over a two-year term.

Mergers and Acquisitions

  • Merck Group (Darmstadt, Germany) to acquire SpringWorks Therapeutics (CT, USA) for $1.4B to accelerate the sustainable growth of its healthcare business.
  • CB Biotechnology (United States) to acquire Theratechnologies (Montreal, Canada) for $254M to expand its pharmaceutical portfolio and enhance patient access.
  • AbbVie (IL, USA) to acquire Capstan Therapeutics (CA, USA) for $250M to strengthen the commitment to advancing genetic medicine in immunology.
  • Channel Therapeutics (NJ, USA) to acquire Pelthos Therapeutics (NC, USA) for $50.1M to commercialize ZELSUVMI™, the first FDA-approved at-home treatment for molluscum contagiosum.
  • Biofrontera (MA, USA) to acquire rights from Biofrontera AG (Leverkusen, Germany) for $11M to restructure the partnership and gain greater control over U.S. operations.
  • Concentra Biosciences (MA, USA) to acquire IGM Biosciences (CA, USA) for $1.247 per share plus a contingent value right for strategic expansion in biotechnology.
  • BerGenBio (Bergen, Norway) to acquire Oncoinvent (Oslo, Norway) to advance radiopharmaceutical cancer therapies and strengthen the oncology pipeline.
  • HealthpointCapital (NY, USA) to acquire ImmersiveTouch (IL, USA) to expand capabilities in extended reality surgical technology.
  • Verge Medical (CA, USA) to acquire ROVO System from Incept LLC (CA, USA) to advance peripheral embolic protection technology.
  • Esteve (Barcelona, Spain) to acquire medicine for the treatment of medullary thyroid cancer from Radius Health (MA, USA) to expand its oncology portfolio and strengthen its presence in rare diseases.
  • Medicus Pharma (Toronto, Canada) to acquire Antev Limited (London, United Kingdom) to expand its clinical pipeline in the treatment of benign prostatic hyperplasia and lower urinary tract symptoms.
  • LicorBio (NE, USA) to acquire Serva Electrophoresis (Heidelberg, Germany) to expand its portfolio in proteomics and life science tools.
  • Innovia Medical (MN, USA) to acquire Grace Medical (TN, USA) to expand specialty surgical solutions in ENT.
  • Innovia Medical (MN, USA) to acquire Hurricane Medical (FL, USA) to expand specialty surgical solutions in Ophthalmology.
  • Alembic Pharmaceuticals (Vadodara, India) to acquire Utility Therapeutics (Altrincham, United Kingdom) to expand its infectious disease pipeline and gain access to FDA-approved antibiotics.

Partnerships

  • Unnatural Products (CA, USA) and Argenx (MA, USA) announced a ~$1.5B strategic research collaboration to discover and develop oral macrocyclic peptide drugs against historically undruggable targets using UNP’s AI-enhanced macrocycle platform.
  • BioVersys AG (Basel, Switzerland) and Shionogi (Osaka, Japan) announced a ~$540.6M research and exclusive license option agreement to jointly develop novel ansamycin antibiotics for non-tuberculous mycobacteria infections from BioVersys’ BV500 program.
  • Apellis Pharmaceuticals (MA, USA) to receive ~$300M from Sobi – Swedish Orphan Biovitrum AB (Stockholm, Sweden) through a royalty purchase agreement as part of their ex-U.S. partnership for Aspaveli®, supporting commercialization efforts in rare kidney diseases including C3G and IC-MPGN.
  • HanchorBio (Taipei, Taiwan) and Henlius (Shanghai, China) announced a $202M exclusive licensing agreement for HCB101, a next-generation SIRPα-IgG4 Fc fusion protein designed to block CD47 signaling and activate anti-tumor immunity, covering Greater China, Southeast Asia, and MENA regions.
  • Neurizon (Melbourne, Australia) and Elanco (IN, USA) announced a ~$79.95M exclusive global licensing agreement to develop and commercialize NUZ-001 for neurodegenerative diseases using Elanco’s Monepantel data package.
  • MaaT Pharma (Lyon, France) and Clinigen (London, United Kingdom) announced a ~$30.6M exclusive European licensing and commercial supply agreement for Xervyteg® (MaaT013), aimed at accelerating access to this microbiome therapy for steroid-resistant acute Graft-versus-Host Disease ahead of potential EMA approval by mid-2026.
  • Verrica Pharmaceuticals (PA, USA) and Torii Pharmaceutical (Japan) announced an expanded collaboration worth up to $18M in milestone payments to initiate a global Phase 3 trial of YCANTH® for common warts and support its regulatory approval in Japan for molluscum contagiosum.
  • Nxera Pharma (Tokyo, Japan) to receive $4.8M in milestone payments from Centessa Pharmaceuticals (MA, USA) under their orexin agonist collaboration, following FDA clearance of the IND and initiation of a Phase 1 trial for Centessa’s OX2R agonist ORX142.
  • Alpha Fusion (Tokyo, Japan) and Curadh MTR (PA, USA) announced a strategic joint venture to globally develop Astatine-211 radiopharmaceuticals, combining Alpha Fusion’s discovery and clinical progress in Japan with Curadh’s expertise in radiopharmaceutical development and U.S. market expansion.
  • Revolution Medicines (CA, USA) and Summit Therapeutics, Inc. (FL, USA) announced a clinical collaboration to evaluate combinations of Revolution’s RAS(ON) inhibitors with Summit’s PD-1/VEGF bispecific antibody ivonescimab in solid tumors, including NSCLC, PDAC, and CRC.
  • Alvotech (Reykjavík, Iceland) and Advanz Pharma (London, United Kingdom) announced a commercialization agreement for AVT10, a biosimilar to Cimzia®, covering European markets and expanding their partnership across more than ten biologic products.
  • Brii Biosciences (NC, USA) and Joincare Pharmaceutical Group Industry Co., Ltd. (Shenzhen, China) announced a licensing agreement to develop and commercialize BRII-693, a novel synthetic lipopeptide for drug-resistant gram-negative infections in Greater China.

Initial Public Offering (IPO)

  • CapsoVision (CA, USA) raised $27.5M through its initial public offering to support the commercialization of its capsule endoscopy solutions and advance the development of its AI-enabled imaging pipeline, including CapsoCam Colon.

Registered Direct Offering (RDO)

  • Curis (MA, USA) raised $7M through a registered direct offering and concurrent private placement to support research, development, and general corporate purposes.

Closures and Layoffs

  • 4D Molecular Therapeutics (CA, USA) to lay off approximately 25% of employees to streamline operations and offset costs associated with accelerated Phase 3 development of 4D-150 for wet AMD.
  • Oncternal Therapeutics (CA, USA) has announced it will close for strategic wind-down and asset sale.
  • Sage Therapeutics (MA, USA) to lay off 338 employees for workforce reduction following acquisition by Supernus Pharmaceuticals.
  • Bristol Myers Squibb (NJ, USA) to lay off 68 employees for cost-cutting as part of a $3.5B reorganization plan.

Is there anything else you’d love to see here or have added to the platform? Please don’t hesitate to contact us with your feedback.